Exelixis Inc (EXEL) (Q3 2026) Earnings Call Highlights: CABOMETYX Momentum
Exelixis Inc (EXEL) reported Q3 2026 earnings, highlighting delays in zanzalintinib's PDUFA date to March 2027 and STELLAR-304 results to Q1 2027. Full-year 2026 revenue guidance was maintained but reflects reduced expectations due to temporal NET indication revenue. CABOMETYX sales grew 6% quarter-over-quarter, with gross-to-net deductions projected at 30%. The company addressed competition, clinical trials, and the 340B program's minimal impact.
How this was made
The 30-second read
Why it matters
The most tradable update is the shift in the zanzalintinib PDUFA action date to March 3, 2027 and the expectation that STELLAR-304 top-line results arrive in Q1 2027, both of which move the company’s catalyst calendar. Management also maintained FY26 revenue guidance but acknowledged a reduction versus prior guidance due to the temporal nature of the NET indication and associated revenue growth, and flagged CABOMETYX gross-to-net deductions near 30%.
Market read
Investors trading EXEL around event risk should focus on the moved FDA and trial timelines and the guidance reduction drivers (NET timing and gross-to-net deductions).
What to watch
The article notes gross-to-net deductions for CABOMETYX around 30% and guidance reduction tied to NET indication timing, which may matter more for near-term margin expectations than the headline delays alone.
Background
The piece summarizes Exelixis’ Q3 2026 earnings call, focusing on zanzalintinib regulatory timing and STELLAR-304/316 clinical program updates, plus CABOMETYX commercial momentum.
Ticker impact
Exelixis updated the PDUFA action date for zanzalintinib to March 3, 2027 and pushed STELLAR-304 top-line results to Q1 2027, signaling delayed catalysts.
Likely downside bias as investors reprice the timing of regulatory and clinical catalysts, despite continued CABOMETYX sales momentum.
The article discloses two explicit timeline shifts (PDUFA date and Q1 2027 top-line) that directly affect the company’s near-term event calendar, while FY26 revenue guidance is maintained but reduced versus prior due to NET indication timing.
Market effects
Biotech investors may further discount event-driven timelines for oncology programs, especially where FDA review dates and trial readouts slip.
Limited direct regional impact; primarily affects US-listed biotech sentiment.
Mostly company-specific, with read-across to RCC/CRC competitive dynamics rather than global macro drivers.
Counterpoint
Maintained FY26 revenue guidance and stated CABOMETYX momentum could outweigh timing slips if investors believe the delays are manageable and do not impair eventual label expansion.
Key entities
- companyExelixis Inc
US-listed biotech whose earnings call highlighted delays for zanzalintinib FDA review and STELLAR-304 top-line results, alongside CABOMETYX momentum.
- drug_programzanzalintinib
Exelixis oncology candidate in colorectal cancer with an updated PDUFA action date of March 3, 2027.
- productCABOMETYX
Exelixis commercial oncology product referenced for sales momentum and gross-to-net deductions.
- clinical_trialSTELLAR-304
Non-clear cell RCC study whose top-line results are now expected in Q1 2027.
- clinical_trialSTELLAR-316
CRC study discussed regarding regimen contribution and expected performance of zanza plus pembro.
